Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204072 · ClinicalTrials.gov registry record · Phase 1
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
A Phase 1 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT02204072 is a Phase 1 study of Prostatic Neoplasms, Castration-Resistant that has completed, run by Boehringer Ingelheim. The registered enrollment target is 120 participants, below the 729-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT02204072, a Phase 1 study of Prostatic Neoplasms, Castration-Resistant, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treated and failed on docetaxel and abiraterone treatments. Initially, a tolerability and safety phase (phase Ib escalation) will be performed to confirm the maximum tolerated dose (MTD), or recommended doses of both BI 836845 and enzalutamide that can be taken together. Once the MTD, or recommended phase II dose, have been determined an expansion cohort will also be explored (phase Ib expansion) in CRPC patients already taking enzalutamide and have a rise in prostate serum antigen (PSA) levels. Patients may not have received prior docetaxel or abiraterone. Patients in this cohort will receive the MTD, or recommended phase II dose, of BI 836845 and enzalutamide determined in the phase Ib escalation phase. The randomised trial (phase II) will be an open label, parallel group study design in a 1:1 ratio to which patients will receive either BI 836845 plus enzalutamide (Arm A) at the MTD/recommended doses, or enzalutamide alone (Arm B). In all parts of the trial safety, anti-tumour activity will be assessed, in addition to circulating tumour cells (CTC), prostate serum antigen (PSA) response and progression, and determination of Overall Survival (OS).
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG BI 836845
Study Locations (20)
Other
- Prince of Wales Hospital - Hong Kong
- Queen Mary Hospital - Hong Kong
- Erasmus MC - Daniel den Hoed - Rotterdam
- Tweesteden Ziekenhuis, locatie Tilburg - Tilburg
- National Cancer Centre Singapore - Singapore
- OncoCare Cancer Centre - Singapore
- Tan Tock Seng Hospital - Singapore
- Samsung Medical Center - Seoul
- Asan Medical Center - Seoul
- Hospital Vall d'Hebron - Barcelona
- Hospital Clínic de Barcelona - Barcelona
- Hospital Santa Creu i Sant Pau - Barcelona
- Hospital Duran i Reynals - L'Hospitalet de Llobregat
- Hospital General Universitario Gregorio Marañón - Madrid
- Hospital Ramón y Cajal - Madrid
- Instituto Valenciano de Oncología - Valencia
- Taichung Veterans General Hospital - Taichung
Michigan
- Karmanos Cancer Institute - Detroit
New York
- NewYork-Presbyterian/Weill Cornell Medical Center - New York
Oregon
- Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02204072
The ClinicalTrials.gov registry entry for NCT02204072 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (84% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02204072 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02204072 about?
NCT02204072 is a clinical study titled "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)". The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treat...
What is the current status of trial NCT02204072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2014-11-11. Estimated completion is 2023-06-01.
What conditions does trial NCT02204072 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT02204072?
The interventions under investigation include: Enzalutamide (DRUG), BI 836845 (DRUG).
Who is sponsoring clinical trial NCT02204072?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02204072 being conducted?
This trial has 20 study locations across Michigan, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RECRUITING · Phase 1
-
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.